for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zosano Pharma Corp

ZSAN.O

Latest Trade

0.63USD

Change

-0.01(-0.80%)

Volume

81,552

Today's Range

0.62

 - 

0.63

52 Week Range

0.33

 - 

3.06

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.63
Open
0.62
Volume
81,552
3M AVG Volume
21.28
Today's High
0.63
Today's Low
0.62
52 Week High
3.06
52 Week Low
0.33
Shares Out (MIL)
115.59
Market Cap (MIL)
73.31
Forward P/E
-2.38
Dividend (Yield %)
--

Next Event

Q3 2021 Zosano Pharma Corp Earnings Release

Latest Developments

More

Zosano Pharma Granted Type C Meeting With FDA Regarding NDA Resubmission For M207 Following Preliminary Top-Line Pharmacokinetic Study Results

Zosano Pharma Posts Q2 Loss Per Share Of $0.06

Zosano Pharma Reports First Quarter 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zosano Pharma Corp

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its ransdermal microneedle system (the System). The System is designed to facilitate drug absorption into the bloodstream. The Company’s lead product candidate is Qtrypta (M207). Qtrypta is a formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is a serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract. Its same formulation, development name C213, is the treatment to provide relief for cluster headache.

Industry

Biotechnology & Drugs

Contact Info

34790 Ardentech Ct

FREMONT, CA

94555-3657

United States

+1.510.7451200

http://www.zosanopharma.com/

Executive Leadership

Steven Lo

Chief Executive Officer, Director

Christine E. Matthews

Chief Financial Officer, Principal Financial Officer

Hayley Lewis

Senior Vice President - Operations

Dushyant Pathak

Senior Vice President - Business Development

Eric Scharin

Vice President - Technical Operations

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-3.740

2019

-2.290

2020

-0.490

2021(E)

-0.267
Price To Earnings (TTM)
--
Price To Sales (TTM)
109.41
Price To Book (MRQ)
1.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
16.40
LT Debt To Equity (MRQ)
5.19
Return on Investment (TTM)
-77.10
Return on Equity (TTM)
-57.24

Latest News

Latest News

FDA delays decision on Spectrum Pharma's drug candidate due to travel curbs

The U.S. health regulator has deferred a decision on Spectrum Pharmaceuticals' <SPPI.O> drug candidate to treat chemotherapy induced loss of white blood cells in cancer patients due to COVID-19 related travel curbs, the company said on Monday.

REFILE-UPDATE 1-FDA declines to approve Zosano's drug for relieving migraine headaches

The U.S. health regulator has declined to approve Zosano Pharma Corp's experimental treatment to relieve pain after the onset of migraine headaches, citing issues with its delivery during clinical trials, the company said on Wednesday.

FDA declines to approve Zosano's treatment for relieving migraine headaches

The U.S. Food and Drug Administration on Wednesday declined to approve Qtrypta, Zosano Pharma Corp's experimental treatment to relieve pain after the onset of migraine headaches, citing issues with the drug delivery during clinical trials.

BRIEF-Zosano Pharma Files Prospectus Supplement Related To Potential Offering Of Common Stock Of Upto $20 Million

* ZOSANO PHARMA FILES PROSPECTUS SUPPLEMENT RELATED TO POTENTIAL OFFERING OF COMMON STOCK OF UPTO $20 MILLION - SEC FILING Source text: (https://bit.ly/3f1gjaL) Further company coverage:

BRIEF-Zosano Pharma Reports Q1 Loss Per Share Of $0.24

* ZOSANO PHARMA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Zosano Pharma Announces The Appointment Of Christine Matthews As Chief Financial Officer

* ZOSANO PHARMA ANNOUNCES THE APPOINTMENT OF CHRISTINE MATTHEWS AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Zosano Pharma Entered Into A Note With Silicon Valley Bank Pursuant To PPP

* ZOSANO PHARMA CORP - ON APRIL 21, ENTERED INTO A NOTE WITH SILICON VALLEY BANK PURSUANT TO PPP WHICH PROVIDES FOR A LOAN IN AMOUNT OF $1.6 MILLION Source text: [https://bit.ly/2S1RceJ] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Zosano Pharma Says Nasdaq Has Determined To Toll Listing Compliance Period Through June 30

* ZOSANO PHARMA - ON APRIL 17, GOT NOTICE FROM NASDAQ THAT EFFECTIVE APRIL 16, NASDAQ HAS DETERMINED TO TOLL LISTING COMPLIANCE PERIOD THROUGH JUNE 30

BRIEF-Zosano Pharma Corp Files For Mixed Shelf Of Up To $74.5 Million

* ZOSANO PHARMA CORP FILES FOR MIXED SHELF OF UP TO $74.5 MILLION – SEC FILING Source text: (https://bit.ly/2wZvQY1) Further company coverage:

BRIEF-Zosano Pharma Reports Q4 Loss Per Share Of $0.46

* ZOSANO PHARMA REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS

BRIEF-Zosano Pharma Says Delivered Notice Of Termination Of Sales Agreement To BTIG

* ZOSANO PHARMA - DELIVERED NOTICE OF TERMINATION OF SALES AGREEMENT TO BTIG BECAUSE IT DOES NOT INTEND TO RAISE ADDITIONAL CAPITAL THROUGH OFFERING Source: (http://bit.ly/2Q33v9Z) Further company coverage:

BRIEF-Zosano Pharma Announces FDA Acceptance Of New Drug Application For Qtrypta For The Acute Treatment Of Migraine

* ZOSANO PHARMA ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR QTRYPTA™ FOR THE ACUTE TREATMENT OF MIGRAINE

BRIEF-Zosano Pharma Announces Pricing Of $8 Million Public Offering Of Common Stock And Warrants

* ZOSANO PHARMA ANNOUNCES PRICING OF $8.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Zosano Pharma Says Had About $4.9 mln In Cash And Cash Equivalents As Of Jan.31

* ZOSANO PHARMA CORP - AS OF JANUARY 31, 2020, COMPANY HAD APPROXIMATELY $4.9 MILLION IN CASH AND CASH EQUIVALENTS Source: (https://bit.ly/37hRqU1) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up